These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19305708)

  • 1. Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.
    Morgan S; Evans RG; Hanley GE; Caetano PA; Black C
    Healthc Policy; 2006 Nov; 2(2):115-27. PubMed ID: 19305708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Income-based drug coverage in British Columbia: the impact on private and public expenditures.
    Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e129-53. PubMed ID: 19305696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.
    Hanley GE; Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e170-86. PubMed ID: 19305698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Income-based drug coverage in british columbia: towards an understanding of the policy.
    Morgan S; Coombes M
    Healthc Policy; 2006 Nov; 2(2):92-108. PubMed ID: 19305707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Income-based drug coverage in British Columbia: the impact on access to medicines.
    Caetano PA; Raymond CB; Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e154-69. PubMed ID: 19305697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Barer M; Reid RJ
    Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):54-63. PubMed ID: 19305768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):e128-53. PubMed ID: 19305760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare".
    Rawson NSB
    Int J Health Policy Manag; 2020 Dec; 9(12):524-527. PubMed ID: 32610769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
    Coombes ME; Morgan SG; Barer ML; Pagliccia N
    Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
    Daw JR; Morgan SG
    Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. British Columbia hospitals: examination and assessment of payment reform (B-CHeaPR).
    Sutherland JM; McGrail KM; Law MR; Barer ML; Crump RT
    BMC Health Serv Res; 2011 Jun; 11():150. PubMed ID: 21702947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.
    Wang PS; Patrick AR; Dormuth C; Maclure M; Avorn J; Canning CF; Schneeweiss S
    J Ment Health Policy Econ; 2010 Mar; 13(1):37-44. PubMed ID: 20571181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
    Brandt J; Shearer B; Morgan SG
    J Pharm Policy Pract; 2018; 11():28. PubMed ID: 30443371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications?
    Allin S; Law MR; Laporte A
    Health Policy; 2013 May; 110(2-3):147-55. PubMed ID: 23522381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Romanow pharmacare: last-dollar first...first-dollar lost?
    Morgan SG; Willison DJ
    Healthc Pap; 2004; 4(3):10-20. PubMed ID: 15114064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis.
    Miregwa BN; Holbrook A; Law MR; Lavis JN; Thabane L; Dolovich L; Wilson MG
    CMAJ Open; 2022; 10(3):E848-E855. PubMed ID: 36167420
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.